Table 2.

GBS Cases after COVID-19 Reported in Japan.

Reference	Age (y)	Sex	Clinical features	Autonomic dysfunction	Gd enhancement on brain MRI	GBS electrophysiological subtype	Serum anti-glycolipid antibody	Cerebrospinal fluid
(10)	69	M	Absent cough reflex, limb weakness, limb areflexia	Unremarkable	Not tested	Not described	anti-Gal-C antibody	TP 202 mg/dL, cell 1/μL
(13)	54	F	Limb weakness, numbness, lower limb areflexia	Not documented	Not tested	Axonal type	Negative	Normal protein levels and cell counts
Present case	22	M	Limb weakness, limb hypoesthesia, dysarthria, dysphagia, left-sided facial numbness, dysautonomia	Positive pilocarpine test, marked fluctuations in blood pressure and heart rate	Bilateral facial nerves	AIDP	Negative	TP 307 mg/dL, cell 5/μL

GBS: Guillain-Barré syndrome, COVID-19: coronavirus disease 2019, Gd: gadolinium, Gal-C: galactocerebroside, TP: total protein, SARS-CoV-2: severe acute respiratory syndrome coronavirus 2, PCR: polymerase chain reaction, AIDP: acute inflammatory demyelinating polyneuropathy, M: male, F: female